V. Surmont
Katholieke Universiteit Leuven
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by V. Surmont.
Lung Cancer | 2002
V. Surmont; Rob J. van Klaveren; Peter J.C.M. Nowak; Pieter E. Zondervan; Henk C. Hoogsteden; Jan P. van Meerbeeck
Pulmonary blastoma (PB) is a rare malignant tumor of the lung. Treatment is primarily surgical, although, combination chemotherapy has been reported to result in objective responses in inoperable tumors or after incomplete resections. To our knowledge, this is the first report of a very radiosensitive PB, which showed major tumor reduction after several fractions of radiotherapy without further tumor regression after additional chemotherapy with cisplatin and etoposide. The literature on the treatment of PB is reviewed.
Rehabilitation Research and Practice | 2010
Bihiyga Salhi; Ingel K. Demedts; A. Simpelaere; S. Decraene; Karim Vermaelen; V. Surmont; J. Van Meerbeeck; Eric Derom
Introduction. Respiratory cancer and its treatment are known to contribute to muscle weakness and functional impairment. Aim. To assess the effects of rehabilitation in patients with respiratory cancer. Methods. Radically treated respiratory cancer patients were included in a 12-week multidisciplinary rehabilitation program. Results. 16 patients (age: 61 ± 7 years; FEV1: 57 ± 16% pred.) showed a reduced exercise tolerance (VO2max: 56 ± 15% pred.; 6 MWD: 67 ± 11% pred.), muscle force (PImax: 54 ± 22% pred.; QF: 67 ± 16% pred.), and quality of life (CRDQd: 17 ± 5 points; CRDQf: 16 ± 5 points). Exercise tolerance, muscle force, and quality of life improved significantly after rehabilitation. Conclusion. Radically treated patients with respiratory cancer have a decreased exercise capacity, muscle force, and quality of life. 12 weeks of rehabilitation leads to a significant improvement in exercise capacity, respiratory muscle force, and quality of life.
Radiotherapy and Oncology | 2016
Pieter Deseyne; Yolande Lievens; W. De Gersem; P. Berkovic; M. Van Eijkeren; V. Surmont; Cristina Derie; B. Goddeeris; W. De Neve; Katrien Vandecasteele
ESTRO 35 2016 _____________________________________________________________________________________________________ using coplanar beams with 6 MV photons and the treatment was performed with DHX LINAC, VARIAN System. Pretreatment kV CBCT images were obtained at 1, 2 and 3 day of irradiations set-up corrections were made before treatment if the translational setup error was greater than 3 mm in any direction. Subsequently a weekly kV CBCT was repeated for whole duration of treatment.
Journal of Clinical Oncology | 2010
Rabab Gaafar; V. Surmont; Giorgio V. Scagliotti; R.J. van Klaveren; Demetris Papamichael; Jack Welch; Baktiar Hasan; Valter Torri; J. Van Meerbeeck
Lung Cancer | 2005
Ellen Pouw; D. van den Bogaert; G. van Wijhe; Rene Vernhout; V. Surmont; R.J. van Klaveren
Journal of Thoracic Oncology | 2018
Jo Raskin; V. Surmont; Baktiar Hasan; E. De Maio; P. Van Schil; J. Van Meerbeeck
Lung Cancer | 2017
Corinne Faivre-Finn; M. Snee; L. Ashcroft; Wiebke Appel; Fabrice Barlesi; Adityanarayan Bhatnagar; Andrea Bezjak; Felipe Cardenal; Pierre Fournel; S. Harden; C. Le Pechoux; R. McMenemin; N. Mohammed; M. O'Brien; Jason R. Pantarotto; V. Surmont; J. Van Meerbeeck; Penella J. Woll; Paul Lorigan; Fiona Blackhall
Radiotherapy and Oncology | 2012
Katrien Vandecasteele; P. Berkovic; I. Madani; Karim Vermaelen; J. Van Meerbeeck; V. Surmont; W. De Neve
MINERVA PNEUMOLOGICA | 2012
V. Surmont; Jan P. van Meerbeeck
Ejc Supplements | 2009
V. Surmont; Kris Nackaerts; S. Senan; Cj Kraaij; Nadia Chouaki; R.J. van Klaveren; J. Vansteenkiste; Egbert F. Smit
Collaboration
Dive into the V. Surmont's collaboration.
European Organisation for Research and Treatment of Cancer
View shared research outputs